The present invention relates to macromolecular transition metal complexes, characterized by having the general formula (I), to the process for their preparation, and to bidentate and monodentate macroligands. The invention also refers to pharmaceutical compositions and medicaments containing said macromolecular transition metal complexes, and to the use of said pharmaceutical compositions, medicaments and macromolecular transition metal complexes for cancer therapy and/or cancer prevention, as antitumor agent in solid tumors, liquid tumors and/or metastases and/or as radiosensitizer agents.

Disclosed herein is a method for selectively reducing, using electrical energy, CO.sub.2 to carbon monoxide or formic acid, a catalyst for use in the method, and an electrochemical reduction system. The method for producing carbon monoxide or formic acid by electrochemically reducing carbon dioxide of the present invention includes (a) reacting carbon dioxide with a metal complex represented by formula (1), and (b) applying a voltage to a reaction product of the carbon dioxide and the metal complex represented by formula (1):

##STR00001##

Disclosed herein is a method for selectively reducing, using electrical energy, CO.sub.2 to carbon monoxide or formic acid, a catalyst for use in the method, and an electrochemical reduction system. The method for producing carbon monoxide or formic acid by electrochemically reducing carbon dioxide of the present invention includes (a) reacting carbon dioxide with a metal complex represented by formula (1), and (b) applying a voltage to a reaction product of the carbon dioxide and the metal complex represented by formula (1):

##STR00001##

The present invention relates to metal complexes bearing at least one (E-E′)-4,4′-bisstyryl-2,2′-bipyridine ligand (LIG1) of the following formula (I): or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates to pharmaceutical compositions comprising these complexes and at least one pharmaceutically acceptable excipient. The present invention also relates to the use of compounds of formula (I) or pharmaceutical compositions comprising thereof as drug and as photosensitizer agent in photodynamic therapy. The present invention relates to methods of preparation of said complexes.

##STR00001##

Disclosed herein are compositions of a deep eutectic solvent with a host, such as a supramolecular host, and the use of the composition to form a composition comprising the host in complex with one or more guests. The deep eutectic solvent provides an alternative medium to the aqueous-based media that have been used in the art to date. Also disclosed are compositions of a deep eutectic solvent with a redox-active compound, such as a viologen compound, and the use of the composition, for example, in a smart window or for agricultural use, such as in an agricultural product.

Disclosed herein are compositions of a deep eutectic solvent with a host, such as a supramolecular host, and the use of the composition to form a composition comprising the host in complex with one or more guests. The deep eutectic solvent provides an alternative medium to the aqueous-based media that have been used in the art to date. Also disclosed are compositions of a deep eutectic solvent with a redox-active compound, such as a viologen compound, and the use of the composition, for example, in a smart window or for agricultural use, such as in an agricultural product.

Provided herein are compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R.sup.1, R.sup.2, R.sup.3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.

##STR00001##

Provided herein are compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R.sup.1, R.sup.2, R.sup.3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.

##STR00001##

The present invention relates to an electrochromic compound, and an electrochromic composition and an electrochromic device, including the same. The electrochromic compound according to the present invention may achieve excellent black coloring effects and excellent curing characteristics, and thus may be used advantageously in an electrochromic device.

The present invention relates to an electrochromic compound, and an electrochromic composition and an electrochromic device, including the same. The electrochromic compound according to the present invention may achieve excellent black coloring effects and excellent curing characteristics, and thus may be used advantageously in an electrochromic device.